Retreatment with onabotulinumtoxinA is not associated with an increased risk of clean intermittent catheterisation: Pooled post hoc analysis

By: Cruz F.¹, Rovner E.², Sobol J.³, Mccammon K.⁴, Hamid R.⁵, Radomski S.⁶, Orejudos A.⁷, Aboushwareb T.⁸, Lemack G.⁹
¹Hospital S. João & Faculty of Medicine of Porto/IBMC Porto, Dept. of Urology, Porto, Portugal, ²Medical University of South Carolina Health Urology Services, Dept. of Urology, Charleston, SC, United States of America, ³Michigan Institute of Urology, Dept. of Urology, West Bloomfield, MI, United States of America, ⁴Eastern Virginia Medical School, Dept. of Urology, Virginia Beach, VA, United States of America, ⁵University College London Hospitals, Dept. of Urology, London, United Kingdom, ⁶University of Toronto, Dept. of Urology, Toronto, ON, Canada, ⁷Allergan, Statistics, Irvine, CA, United States of America, ⁸Allergan, Dept. of Urology, Irvine, CA, United States of America, ⁹University of Texas Southwestern Medical Center, Dept. of Urology and Neurology, Dallas, TX, United States of America

Programming settings and recharge interval in a prospective study of a rechargeable sacral neuromodulation system for the treatment of overactive bladder

By: Van Kerrebroeck P.E.¹, De Wachter S.², Ruffion A.³, Van Der Aa F.⁴, Perrouin-Verbe M-A.⁵, Jairam R.⁶, Elneil S.⁷, Blok B.⁸
¹Maastricht UMC, Dept. of Urology, Maastricht, Netherlands, The, ²University Hospital Antwerpen, Dept. of Urology, Edegem, Belgium, ³Hôpital Lyon Sud, Pierre Bénite, Dept. of Urology, Lyon, France, ⁴UZ Leuven, Dept. of Urology, Leuven, Belgium, ⁵University Hospital of Nantes, Dept. of Urology, Nantes, France, ⁶Maastricht University Medical Centre, Dept. of Urology, Maastricht, Netherlands, The, ⁷National Hospital of Neurology and Neurosurgery, Dept. of Uro-Neurology, London, United Kingdom, ⁸Erasmus MC, Dept. of Urology, Rotterdam, Netherlands, The

Treatment of overactive bladder with a miniaturized rechargeable sacral neuromodulation system

By: Blok B.F.M.¹, Van Kerrebroeck P.², De Wachter S.³, Ruffion A.⁴, Van Der Aa F.⁵
Efficacy and tolerance of botulinum toxin injections after sacral nerve stimulation failure for idiopathic overactive bladder

By: Baron M., Delcourt C., Pfister C., Grise P., Cornu J-N.
Charles Nicolle Hospital, Dept. of Urology, Rouen, France

OnabotulinumtoxinA for neurogenic detrusor overactivity not only reduces the frequency and severity of autonomic dysreflexia safely but significantly improves quality of life for individuals with spinal cord injury

By: Walter M., Kran S., Nigro M., Stothers L., Rapoport D., Kavanagh A., Krassioukov A.
University of British Columbia, Urologic Sciences, Vancouver, Canada

Cycling sacral root neuromodulation: Pilot study to assess the effectiveness of this mode in neuromodulator programming for the treatment of chronic pelvic pain syndrome

1Azienda ospedaliera universitaria integrata Verona, Dept. of Urology, Verona, Italy,
2Medical University of Vienna International, Dept. of Nation Hospital, Abu Dabi, United Arab Emirates,
3Azienda Ospedaliera Universitaria Integrata, Dept. of Urology, Verona, Italy,
4Medical University of Vienna International, Dept. of Urology and Neurourology, Abu Dabi, United Arab Emirates,
5Nation Hospital, Dept. of Anesthesiology, Abu Dabi, United Arab Emirates,
6Nation Hospital Abu Dhabi, Dept. of Radiology, Abu Dabi, United Arab Emirates,
7Nation Hospital Abu Dhabi, Dept. of Physiotherapy, Abu Dabi, United Arab Emirates,
8Nation Hospital Abu Dhabi (UAE), Dept. of Obstetrics and Gynecology, Abu Dabi, United Arab Emirates

Another therapeutic role for intravesical botulinum toxin A: Patients with severe bladder spasm with long stay catheters

By: Young M., Osman N., Philips L., Mangera A., Reid S., Inman R., Chapple C.
Sheffield Teaching Hospitals, Dept. of Urology, Sheffield, United Kingdom

Outcomes of use of intravesical abobotulinumtoxinA (Dysport®) for treatment of overactive bladder – a prospective study
Scientific Programme - EAU18 Copenhagen

956

**Long term follow-up reveals a low persistence rate of abobotulinum toxin A injections for idiopathic OAB**

By: Baron M., Malval B., Pfister C., Grise P., Cornu J-N.
Charles Nicolle Hospital, Dept. of Urology, Rouen, France

957

Withdrawn
To be confirmed

958

**Complications of non-continent cutaneous urinary diversion in adult spinal cord injured patients**

By: Guillot-Tantay C., Chartier-Kastler E., Perrouin-Verbe M-A., Denys P., Léon P., Phé V.
Pitié-Salpêtrière Academic Hospital, Dept. of Urology, Paris, France, Raymond Poincaré Academic Hospital, Physical Medicine and Rehabilitation, Garches, France

959

**Long term follow-up reveals a low persistence rate of abobotulinum toxin A and onabotulinum toxin A injections for neurogenic detrusor overactivity**

Charles Nicolle Hospital, Dept. of Urology, Rouen, France, University of Rennes, Dept. of Urology, Rennes, France, Pitié-Salpêtrière Hospital, Dept. of Physical and Rehabilitation Medicine, Rouen, France, University of Toulouse, Dept. of Urology, Toulouse, France

960

**Long-term outcomes of permanent nitinol urethral stent Memotherm® implantation in neurological patients with detrusor-striated sphincter dyssynergia**

By: Leon Bertrand P., Chartier Kastler E., Ismail S., Denys P., Perrouin-Verbe M., Phé V.
CHU Reims, Dept. of Urology, Reims, France, Pitié-Salpêtrière Hospital, Dept. of Urology, Paris, France, Pitié-Salpêtrière Hospital, Dept. of Urology, Paris, France, Raymond Poincaré University Hospital, Dept. of Physical Medicine and Rehabilitation, Garches, France, Pitié-Salpêtrière Hospital, Dept. of Urology, Paris, France

State-of-the-art lecture Longterm outcome of invasive treatment
G.R. Kasyan, Moscow (RU)